MX2016004963A - Sal y formas cristalinas de inhibidores de quinasa tipo polo-4. - Google Patents

Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.

Info

Publication number
MX2016004963A
MX2016004963A MX2016004963A MX2016004963A MX2016004963A MX 2016004963 A MX2016004963 A MX 2016004963A MX 2016004963 A MX2016004963 A MX 2016004963A MX 2016004963 A MX2016004963 A MX 2016004963A MX 2016004963 A MX2016004963 A MX 2016004963A
Authority
MX
Mexico
Prior art keywords
compound
salt
fumarate
maleate
plk
Prior art date
Application number
MX2016004963A
Other languages
English (en)
Other versions
MX359069B (es
Inventor
Peter Brent Sampson
Heinz W Pauls
Miklos Feher
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MX2016004963A publication Critical patent/MX2016004963A/es
Publication of MX359069B publication Critical patent/MX359069B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se describe una sal fumarato y una sal maleato del compuesto (I) representado por la siguiente fórmula estructural, así como sus composiciones farmacéuticas correspondientes; las formas particulares cristalinas sencillas del compuesto (I) fumarato y el compuesto (I) maleato 1:1 se caracterizan por una variedad de propiedades y mediciones físicas; también se describen métodos de preparación de formas específicas cristalinas del compuesto (I) fumarato 1:1 y el compuesto (I) maleato; la presente invención también proporciona métodos de tratamiento de un sujeto con un cáncer. (ver Fórmula).
MX2016004963A 2013-10-18 2014-10-17 Sal y formas cristalinas de inhibidor de quinasa tipo polo-4. MX359069B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361892564P 2013-10-18 2013-10-18
PCT/CA2014/051001 WO2015054793A1 (en) 2013-10-18 2014-10-17 Salt and crystal forms of plk-4 inhibitor

Publications (2)

Publication Number Publication Date
MX2016004963A true MX2016004963A (es) 2016-06-28
MX359069B MX359069B (es) 2018-09-12

Family

ID=52827507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004963A MX359069B (es) 2013-10-18 2014-10-17 Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.

Country Status (26)

Country Link
US (5) US9884855B2 (es)
EP (1) EP3057965B1 (es)
JP (1) JP6492072B2 (es)
KR (3) KR20160070106A (es)
CN (2) CN105764899B (es)
AU (1) AU2014336929B9 (es)
CA (1) CA2926845C (es)
CY (1) CY1121484T1 (es)
DK (1) DK3057965T3 (es)
EA (1) EA031569B1 (es)
ES (1) ES2718603T3 (es)
HR (1) HRP20190564T1 (es)
HU (1) HUE043194T2 (es)
IL (1) IL245038B (es)
LT (1) LT3057965T (es)
ME (1) ME03377B (es)
MX (1) MX359069B (es)
NZ (1) NZ718744A (es)
PL (1) PL3057965T3 (es)
PT (1) PT3057965T (es)
RS (1) RS58413B1 (es)
SG (1) SG11201602783SA (es)
SI (1) SI3057965T1 (es)
TR (1) TR201902875T4 (es)
TW (1) TWI659952B (es)
WO (1) WO2015054793A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
ES2603613T3 (es) 2010-04-06 2017-02-28 University Health Network Inhibidores de quinasa y su uso en el tratamiento del cáncer
SI3057965T1 (sl) 2013-10-18 2019-04-30 University Health Network Sol in kristalne oblike inhibitorja PLK-4
US20210060026A1 (en) * 2017-09-08 2021-03-04 University Health Network Combination therapies for inhibition of polo-like kinase 4
AU2020264143A1 (en) * 2019-04-24 2021-10-28 University Health Network Crystal form S4 of the PLK4 inhibitor (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 H-imidazol-6- yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one fumarate
CN115397429A (zh) * 2019-12-06 2022-11-25 大学健康网络 急性髓性白血病或骨髓增生异常综合征治疗
TW202309008A (zh) 2021-05-11 2023-03-01 美商歐瑞克製藥公司 類ｐｏｌｏ激酶４抑制劑

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483323A (en) * 1945-08-01 1949-09-27 Kay Fries Chemicals Inc Method of preparing phenyl ethyl alcohol
WO2004037247A1 (en) 2002-10-21 2004-05-06 Irm Llc Oxindoles with anti-hiv activity
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
WO2008118097A1 (en) * 2007-03-23 2008-10-02 Agency For Science, Technology And Research Palladium catalysts
WO2009042711A1 (en) * 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN101970426A (zh) * 2007-12-21 2011-02-09 大学健康网络 吲唑基、苯并咪唑基、苯并三唑基取代的二氢吲哚酮衍生物作为癌症治疗中有用的激酶抑制剂
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
WO2010125004A1 (en) 2009-04-29 2010-11-04 Nerviano Medical Sciences S.R.L. Cdk inhibitor salts
ES2603613T3 (es) 2010-04-06 2017-02-28 University Health Network Inhibidores de quinasa y su uso en el tratamiento del cáncer
WO2012000103A1 (en) * 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
US9012464B2 (en) * 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
US9580390B2 (en) 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
SI3057965T1 (sl) 2013-10-18 2019-04-30 University Health Network Sol in kristalne oblike inhibitorja PLK-4
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer

Also Published As

Publication number Publication date
US20160264559A1 (en) 2016-09-15
US10472353B2 (en) 2019-11-12
EP3057965A4 (en) 2017-05-24
CA2926845C (en) 2023-06-13
US11667627B2 (en) 2023-06-06
CA2926845A1 (en) 2015-04-23
KR20160070106A (ko) 2016-06-17
EP3057965B1 (en) 2019-01-02
TWI659952B (zh) 2019-05-21
JP6492072B2 (ja) 2019-03-27
US20210269428A1 (en) 2021-09-02
HUE043194T2 (hu) 2019-08-28
RS58413B1 (sr) 2019-04-30
EA201690755A1 (ru) 2016-09-30
CY1121484T1 (el) 2020-05-29
NZ718744A (en) 2021-07-30
EA031569B1 (ru) 2019-01-31
WO2015054793A1 (en) 2015-04-23
PT3057965T (pt) 2019-04-23
KR20210137251A (ko) 2021-11-17
US20190248775A1 (en) 2019-08-15
ES2718603T3 (es) 2019-07-03
KR20220063299A (ko) 2022-05-17
US9884855B2 (en) 2018-02-06
SI3057965T1 (sl) 2019-04-30
US20180155335A1 (en) 2018-06-07
CN105764899A (zh) 2016-07-13
AU2014336929B2 (en) 2018-11-22
DK3057965T3 (en) 2019-04-01
PL3057965T3 (pl) 2019-08-30
US20200140428A1 (en) 2020-05-07
US10392374B2 (en) 2019-08-27
EP3057965A1 (en) 2016-08-24
CN105764899B (zh) 2021-06-01
HRP20190564T1 (hr) 2019-05-17
US10919886B2 (en) 2021-02-16
CN113248486A (zh) 2021-08-13
JP2016537326A (ja) 2016-12-01
ME03377B (me) 2020-01-20
KR102395737B1 (ko) 2022-05-10
MX359069B (es) 2018-09-12
SG11201602783SA (en) 2016-05-30
TW201609717A (zh) 2016-03-16
IL245038B (en) 2019-11-28
LT3057965T (lt) 2019-03-12
AU2014336929B9 (en) 2019-03-21
TR201902875T4 (tr) 2019-03-21
IL245038A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
PH12019500480A1 (en) Pyridine compound
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
MX351812B (es) Derivados de piridona.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12016500169A1 (en) Polymorph of syk inhibitors
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
PH12016500225B1 (en) Novel quinoline-substituted compound
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
MX2016002794A (es) Compuestos antiproliferativos.
MD4820B1 (ro) Compuşi dihidroizochinolinonici substituiţi
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
MX2016007810A (es) Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa.
WO2015042414A8 (en) Multicyclic compounds and methods of using same
PH12015501146A1 (en) Hydantoin derivative
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil

Legal Events

Date Code Title Description
FG Grant or registration